INS and type 2 diabetes mellitus: A Canadian claims database study has shown that CGM assists in treatment changes and escalation in patients with T2D to a greater extent than SMBG, with a significant relative risk of treatment progression of 1.86 in non-insulin treatment-naïve patients and 2.03 in non-insulin treatment non-naïve patients (73).